Sep. 5 at 2:15 PM
$ARRXF
November 2025 Set as Turning Point in Archer’s Commercial Journey
For investors, this matters because it could significantly speed up Archer’s path to market. If imec can successfully integrate graphene into traditional chip production, Archer would be able to scale its biosensor technology far more quickly and at lower cost, a major step toward commercialisation.
The first stage of research and development is expected to wrap up by November 2025. This will be a key milestone, marking the transition from concept and testing into prototype development. From there, Archer’s focus will shift toward building a final product ready for widespread use in at-home and point-of-care health testing.
Source: https://stocksdownunder.com/